| Bid | 0.3 |
| Market Cap | 9.49K |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -15.64 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.3 |
| Volume | 88 |
| Avg. Volume (20D) | 1,452 |
| Open | 0.00 |
| Previous Close | undefined |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 0.07 |
| Beta | undefined |
About EVLO
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated in...
Analyst Forecast
According to 1 analyst ratings, the average rating for EVLO stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
1 month ago · businesswire.com
EVLO to Provide Dominion Energy With Safety Enhanced Energy Storage SystemsMONTRÉAL--(BUSINESS WIRE)--EVLO Energy Storage Inc. (EVLO), a fully integrated battery energy storage systems (BESS) provider and wholly owned subsidiary of Hydro-Québec, announces a major achievement...